We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

63 hedge funds and large institutions have $81.6M invested in Aevi Genomic Medicine Inc in 2015 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 9 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 2

211% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 9

49% more capital invested

Capital invested by funds: $54.9M → $81.6M (+$26.7M)

24% more funds holding

Funds holding: 51 → 63 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
63
Holders Change
+12
Holders Change %
+23.53%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
28
Reduced
9
Closed
2
Calls
$284K
Puts
–
Net Calls
+$284K
Net Calls Change
-$29K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$10.2M
2
Jennison Associates
Jennison Associates
New York
+$6.15M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.11M
4
BBA
Baker Bros. Advisors
New York
+$5.19M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.19M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$614K
2
BGA
Belmont Global Advisors
Texas
-$611K
3
Morgan Stanley
Morgan Stanley
New York
-$43K
4
PVH
Psagot Value Holdings
Israel
-$14.9K
5
BA
BlackRock Advisors
Delaware
-$11.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Creative Planning
51
Creative Planning
Kansas
$18K +$14K +2,060 +219%
Simplex Trading
52
Simplex Trading
Illinois
$15K +$17.4K +2,565 New
PCM
53
Penserra Capital Management
California
$14K +$16K +2,363 New
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$12K -$5.25K -773 -27%
KCPG
55
Kavar Capital Partners Group
Kansas
$9K – – –
Citigroup
56
Citigroup
New York
$7K -$835 -123 -9%
KTC
57
Kistler-Tiffany Companies
Pennsylvania
$7K +$7.41K +1,092 New
BKA
58
Brick & Kyle Associates
Pennsylvania
$6K – – –
TWA
59
TCI Wealth Advisors
Arizona
$6K – – –
TRCT
60
Tower Research Capital (TRC)
New York
$3K -$9.42K -1,387 -72%
LTFS
61
Ladenburg Thalmann Financial Services
Florida
$3K – – –
Manulife (Manufacturers Life Insurance)
62
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$38 – – –
Alyeska Investment Group
63
Alyeska Investment Group
Illinois
– -$614K -78,575 Closed
Barclays
64
Barclays
United Kingdom
– -$1K -88 Closed
IA
65
IFP Advisors
Florida
– +$204 +30 New
1 2
3

GNMX Hedge Fund Activity: Q4 2015 in Review

63 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2015, worth a combined $81.6M — up 49% from $54.9M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GNMX positions and 2 closed out — a net gain of 12 holders — while 28 added to existing stakes and 9 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $10.2M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $614K sold.

  • 63 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2015, up from 51 in Q3 2015.
  • Funds reported $81.6M of Aevi Genomic Medicine Inc stock for Q4 2015, up 49% quarter-over-quarter.
  • 14 funds opened new Aevi Genomic Medicine Inc positions in Q4 2015 and 2 closed out, a net change of +12 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2015 was Broadfin Capital, an estimated $10.2M added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2015 was Alyeska Investment Group, an estimated $614K sold.

Based on aggregated 13F filings for Q4 2015.